Receive our newsletter – data, insights and analysis delivered to you
  1. News
August 11, 2021

PGDx and Tesis Labs partner to create new genomics products

PGDx’s pan-cancer solutions allow researchers to identify biomarkers using advanced genomic sequencing.

Personal Genome Diagnostics (PGDx) has collaborated with Tesis Labs to advance cancer profiling and treatment by creating new genomics solutions.

Through this partnership, PGDx and Tesis Labs plan to combine their resources and expertise to create genomics products that will help to fight cancer and improve patient outcomes.

PGDx has developed a portfolio of regulated tissue-based and non-invasive liquid biopsy genomic products for health systems across the world.

Currently, the company offers three pan-cancer next-generation sequencing (NGS) kitted solutions, which consist of elio tissue complete, elio plasma complete and elio plasma resolve.

These solutions allow researchers and clinicians to identify biomarkers and profile tumours using advanced genomic sequencing within their own hospital systems and laboratories.

With labs in Houston, Lafayette, Denver and Colorado, US, Tesis Labs uses a genetically integrated medical platform for genetic sequencing and genetic data collection to support medical specialities.

Content from our partners
“Everything is custom”: Behind the scenes of medical wire solutions
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials

The company aims to provide quality genetic testing and precision medicine to patients, as well as allow healthcare providers and physicians to create personalised care plans to treat each patient’s unique health risks.

Tesis Labs CEO Ron King said: “We are excited to partner with PGDx and leverage our aligned vision and collective expertise to enable new and creative clinical opportunities.

“Genetic sequencing and genetic biomarkers are revealing new opportunities for medicine. Our clinical expertise and approaches to unlocking the power of genetic sequencing are bringing new insights to cancer research, profiling and treatment.”

By 2040, the National Institutes of Health estimates that there will be nearly 29.5 million new cancer cases and around 16.4 million deaths from cancer each year worldwide.

The new collaboration will bring the specialised clinical laboratory and biotechnology teams together to advance cancer predisposition, profiling and treatment.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU